ArticleFrontiers in oncology2026
Hypoxia induced DNMT3B and SHP2 signaling promoted HCC via suppressing P53 and MYH11 protein expression.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This work aims to analyze the intricate process via which CBFβ-MYH11 facilitates the suppression of hepatocellular carcinoma in hypoxic environments. Methods: Three independent HCC cohorts including TCGA-LIHC, GSE14520 and ICGC LIRI-JP were enrolled. Gene correlation analysis, hypoxia-based expression comparison and prognostic stratification analysis were performed. A composite HIF1A/AKT/SHP2/DNMT3B/P53/MYH11 axis score was established to evaluate clinical prognostic value. Bioinformatics analysis was utilized to examine differentially expressed genes in hepatocellular carcinoma. In nude mouse models, tumor volume, tumor cross-sectional area, methylation levels, protein expression, vascular development, scratch assay, invasion assay, chromatin immunoprecipitation, and co-immunoprecipitation were quantitatively assessed. We used methods including HE staining, immunohistochemistry, phosphor-PCR, Western blot, angiogenesis tests, migration assays, and invasion assays. Results: Multi-cohort analysis revealed a stable negative correlation between DNMT3B and MYH11. High HIF1A expression was accompanied by DNMT3B upregulation and MYH11 silencing. Patients in the high axis score group exhibited markedly shorter overall survival, and the axis score served as an independent adverse prognostic risk factor. Bioinformatics analysis reveals MYH11-specific expression in hepatocellular carcinoma. There were clear differences between Huh-7-NC-CBFβ-MYH11 and Huh-7-OE-CBFβ-MYH11 when they were compared. Huh-7-OE-CBFβ-MYH11 showed a smaller tumor volume, less vascular density, fewer invasion cells, a shorter migration distance, and less vascular development. The expression of MMP2, VEGF, and HIF1α showed a decrease, while RUNX1 expression increased. The introduction of an AKT inhibitor in hypoxic conditions resulted in a more pronounced increase in P53 and CBFβ-MYH11 protein expression compared to the SHP2 inhibitor. AKT inhibitors eliminated differences in DNMT3B, HIF1α, and MMP2 expression between normoxia and hypoxia. Conclusion: In hypoxic conditions, CBFβ-MYH11 regulates the AKT/DNMT3B/SHP2 pathway to modulate variations in P53 expression, ultimately hindering the progression of hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.